Which has stronger earnings and valuation, TGTX or MESO?

TG Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67 Mesoblast $120.25M 16.72 -$57.50M -$0.28 N/A

Is MESO or APGE more profitable?

Mesoblast's return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Apogee Therapeutics N/A -29.88% -28.08%

Which has better earnings and valuation, MESO or IMVT?

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $120.25M 16.72 -$57.50M -$0.28 N/A Immunovant N/A N/A -$505.61M -$2.82 N/A

Is MESO or IMVT more profitable?

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Immunovant N/A -69.59% -62.49%

Is MESO or SYRE more profitable?

Mesoblast's return on equity of 0.00% beat Spyre Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Spyre Therapeutics N/A -30.74% -22.23%

Which has preferable earnings & valuation, ALKS or MESO?

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alkermes $1.67B 4.62 $241.66M $0.38 120.97 Mesoblast $120.25M 16.72 -$57.50M -$0.28 N/A

Is ALKS or MESO more profitable?

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Alkermes 3.96% 4.15% 2.19% Mesoblast N/A N/A N/A

Mesoblast (MESO) Competitors

$15.48 -0.02 (-0.13%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$15.49 +0.01 (+0.06%)

As of 09/11/2026 07:30 PM Eastern

Compare

MESO vs. TGTX, APGE, IMVT, SYRE, and ALKS

Should you buy Mesoblast stock or one of its competitors? Mesoblast's main competitors and comparable companies include TG Therapeutics (TGTX), Apogee Therapeutics (APGE), Immunovant (IMVT), Spyre Therapeutics (SYRE), and Alkermes (ALKS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mesoblast compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Mesoblast (NASDAQ:MESO) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

TG Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A

TG Therapeutics has a net margin of 55.22% compared to Mesoblast's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Mesoblast	N/A	N/A	N/A

TG Therapeutics presently has a consensus target price of $63.00, indicating a potential upside of 16.90%. Mesoblast has a consensus target price of $39.00, indicating a potential upside of 151.94%. Given Mesoblast's higher possible upside, analysts plainly believe Mesoblast is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

TG Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its stock price is 112% more volatile than the broader market.

In the previous week, TG Therapeutics had 8 more articles in the media than Mesoblast. MarketBeat recorded 9 mentions for TG Therapeutics and 1 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 0.92 beat Mesoblast's score of 0.77 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TG Therapeutics	Positive
Mesoblast	Positive

Summary

TG Therapeutics beats Mesoblast on 12 of the 16 factors compared between the two stocks.

How does Mesoblast compare to Apogee Therapeutics?

Mesoblast (NASDAQ:MESO) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Mesoblast has higher revenue and earnings than Apogee Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Mesoblast has a beta of 2.12, indicating that its share price is 112% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Apogee Therapeutics	N/A	-29.88%	-28.08%

Mesoblast presently has a consensus target price of $39.00, indicating a potential upside of 151.94%. Apogee Therapeutics has a consensus target price of $126.77, indicating a potential downside of 6.14%. Given Mesoblast's higher probable upside, research analysts clearly believe Mesoblast is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Apogee Therapeutics had 8 more articles in the media than Mesoblast. MarketBeat recorded 9 mentions for Apogee Therapeutics and 1 mentions for Mesoblast. Apogee Therapeutics' average media sentiment score of 1.70 beat Mesoblast's score of 0.77 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Mesoblast	Positive
Apogee Therapeutics	Very Positive

Summary

Apogee Therapeutics beats Mesoblast on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Immunovant?

Mesoblast (NASDAQ:MESO) and Immunovant (NASDAQ:IMVT) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 1.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Mesoblast has a beta of 2.12, suggesting that its stock price is 112% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Immunovant	N/A	-69.59%	-62.49%

In the previous week, Immunovant had 4 more articles in the media than Mesoblast. MarketBeat recorded 5 mentions for Immunovant and 1 mentions for Mesoblast. Immunovant's average media sentiment score of 1.43 beat Mesoblast's score of 0.77 indicating that Immunovant is being referred to more favorably in the news media.

Company	Overall Sentiment
Mesoblast	Positive
Immunovant	Positive

Mesoblast currently has a consensus target price of $39.00, indicating a potential upside of 151.94%. Immunovant has a consensus target price of $44.00, indicating a potential upside of 17.77%. Given Mesoblast's higher possible upside, equities research analysts plainly believe Mesoblast is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Immunovant	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.55

Mesoblast has higher revenue and earnings than Immunovant. Mesoblast is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

Summary

Mesoblast beats Immunovant on 8 of the 14 factors compared between the two stocks.

How does Mesoblast compare to Spyre Therapeutics?

Mesoblast (NASDAQ:MESO) and Spyre Therapeutics (NASDAQ:SYRE) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Mesoblast's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Spyre Therapeutics	N/A	-30.74%	-22.23%

In the previous week, Spyre Therapeutics had 16 more articles in the media than Mesoblast. MarketBeat recorded 17 mentions for Spyre Therapeutics and 1 mentions for Mesoblast. Mesoblast's average media sentiment score of 0.77 beat Spyre Therapeutics' score of 0.70 indicating that Mesoblast is being referred to more favorably in the media.

Company	Overall Sentiment
Mesoblast	Positive
Spyre Therapeutics	Positive

Mesoblast has higher revenue and earnings than Spyre Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Spyre Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A
Spyre Therapeutics	N/A	N/A	-$155.20M	-$1.95	N/A

Mesoblast currently has a consensus target price of $39.00, indicating a potential upside of 151.94%. Spyre Therapeutics has a consensus target price of $109.69, indicating a potential upside of 21.07%. Given Mesoblast's higher probable upside, research analysts clearly believe Mesoblast is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Spyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Mesoblast has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 2.99, meaning that its share price is 199% more volatile than the broader market.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mesoblast beats Spyre Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Mesoblast (NASDAQ:MESO) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation.

In the previous week, Alkermes had 5 more articles in the media than Mesoblast. MarketBeat recorded 6 mentions for Alkermes and 1 mentions for Mesoblast. Alkermes' average media sentiment score of 0.99 beat Mesoblast's score of 0.77 indicating that Alkermes is being referred to more favorably in the media.

Company	Overall Sentiment
Alkermes	Positive
Mesoblast	Positive

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 1.4% of Mesoblast shares are owned by institutional investors. 4.6% of Alkermes shares are owned by insiders. Comparatively, 18.8% of Mesoblast shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.67B	4.62	$241.66M	$0.38	120.97
Mesoblast	$120.25M	16.72	-$57.50M	-$0.28	N/A

Alkermes has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.12, meaning that its share price is 112% more volatile than the broader market.

Alkermes presently has a consensus price target of $54.56, indicating a potential upside of 18.69%. Mesoblast has a consensus price target of $39.00, indicating a potential upside of 151.94%. Given Mesoblast's higher probable upside, analysts plainly believe Mesoblast is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	3.96%	4.15%	2.19%
Mesoblast	N/A	N/A	N/A

Summary

Alkermes beats Mesoblast on 13 of the 17 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.01B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-55.29	14.25	275.24	25.29
Price / Sales	16.72	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	3.53	15.12	10.33	6.20
Net Income	-$57.50M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-10.62%	-4.34%	-3.32%	-2.35%
1 Month Performance	-7.75%	-0.02%	-0.41%	-2.77%
1 Year Performance	4.45%	40.64%	19.21%	7.63%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	1.8292 of 5 stars	$15.48 -0.1%	$39.00 +151.9%	+0.7%	$2.01B	$120.25M	N/A	108
TGTX TG Therapeutics	3.3947 of 5 stars	$55.33 -1.2%	$63.00 +13.9%	+66.0%	$8.50B	$616.29M	20.27	290
APGE Apogee Therapeutics	1.7144 of 5 stars	$135.07 flat	$126.77 -6.1%	N/A	$8.40B	N/A	N/A	91	Positive News
IMVT Immunovant	2.6449 of 5 stars	$40.00 +1.9%	$44.00 +10.0%	+122.4%	$8.26B	N/A	N/A	120	Positive News
SYRE Spyre Therapeutics	2.4172 of 5 stars	$90.79 +2.0%	$109.69 +20.8%	+459.3%	$7.98B	$890K	N/A	73	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. TGTX, APGE, IMVT, SYRE, and ALKS

How does Mesoblast compare to TG Therapeutics?

Summary

How does Mesoblast compare to Apogee Therapeutics?

Summary

How does Mesoblast compare to Immunovant?

Summary

How does Mesoblast compare to Spyre Therapeutics?

Summary

How does Mesoblast compare to Alkermes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. TGTX, APGE, IMVT, SYRE, and ALKS

How does Mesoblast compare to TG Therapeutics?

Do institutionals and insiders have more ownership in TGTX or MESO?

Which has stronger earnings and valuation, TGTX or MESO?

Is TGTX or MESO more profitable?

Do analysts recommend TGTX or MESO?

Which has more risk and volatility, TGTX or MESO?

Does the media favor TGTX or MESO?

Summary

How does Mesoblast compare to Apogee Therapeutics?

Do insiders & institutionals have more ownership in MESO or APGE?

Which has stronger valuation and earnings, MESO or APGE?

Which has more risk & volatility, MESO or APGE?

Is MESO or APGE more profitable?

Do analysts prefer MESO or APGE?

Does the media refer more to MESO or APGE?

Summary

How does Mesoblast compare to Immunovant?

Do insiders & institutionals have more ownership in MESO or IMVT?

Which has more volatility & risk, MESO or IMVT?

Is MESO or IMVT more profitable?

Does the media prefer MESO or IMVT?

Do analysts recommend MESO or IMVT?

Which has better earnings and valuation, MESO or IMVT?

Summary

How does Mesoblast compare to Spyre Therapeutics?

Is MESO or SYRE more profitable?

Does the media refer more to MESO or SYRE?

Which has higher earnings and valuation, MESO or SYRE?

Do analysts rate MESO or SYRE?

Which has more risk and volatility, MESO or SYRE?

Do institutionals & insiders have more ownership in MESO or SYRE?

Summary

How does Mesoblast compare to Alkermes?

Does the media favor ALKS or MESO?

Do institutionals & insiders have more ownership in ALKS or MESO?

Which has preferable earnings & valuation, ALKS or MESO?

Which has more risk & volatility, ALKS or MESO?

Do analysts prefer ALKS or MESO?

Is ALKS or MESO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools